This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. All rights reserved.
Here are some Drug Channels articles with relevant background for the video: The 340B Program Reached $66 Billion in 2023Up 23% vs. 2022: Analyzing the Numbers and HRSAs Curious Actions Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy (..)
for an exclusive deep dive into the latest trends, data, and strategies shaping the pharmacy benefit management (PBM) industry. Pharmacies and Pharmacy Benefit Managers , Dr. Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. Fein, Ph.D., All rights reserved.
Drug Channels Institutes (DCIs) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Once again, specialty mostly means affiliated with a PBM. What do you think?
For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. In fact, nearly all marketed Humira biosimilars are excluded from the larger PBMs 2025 formularies. What do you think?
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Todays guest post is from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx. Divya shares new GoodRx data showing that out-of-pocket costs at the pharmacy counter remain a primary barrier to medication adherence. To learn about GoodRxs prescription abandonment solutions, download Reduce Rx Abandonment at the Pharmacy.
Small pharmacies have ghosted Medicare Part Ds preferred networksno farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Abracadabra!
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. to 1:30 p.m. You can reset the cart by entering 0 in the quantity field.)
You'll learn how money and medicines move between manufacturers, wholesalers, pharmacies, PBMs, and payersand how each relationship affects costs and outcomes. The Economics of Retail, Mail, and Specialty Pharmacies Gain a clear-eyed view of how different pharmacy channels generate revenue and manage costs. All rights reserved.
There was more bad news, as employment in retail pharmacies and drugstores dropped by 8,500 positions in 2024, following a drop of 4,800 positions in 2023. Employment in mass merchants and supermarkets with pharmacies increased. Click here to share your thoughts on the pharmacist job market with the Drug Channels LinkedIn community.
Threes still company in the world of pharmacy benefit managers. Below, we break down the latest market share data from Drug Channels Institute (DCI), explore the developments driving these changes, and examine what they signal for the future of the PBM landscape. Pharmacies and Pharmacy Benefit Managers ends today (3/31/25)!
Pharmacies and Pharmacy Benefit Managers. The total share of the largest 15 companies decreased slightly compared with their 2020 share, due primarily to below-market growth rates at retail and long-term care pharmacies. Read on as we cue up our latest update on the booming pharmacy and PBM marketplace.
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacymarket continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialty pharmacy trends.
In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. to 1:30 p.m. to 1:30 p.m.
Pharmacies and Pharmacy Benefit Managers. prescription dispensing revenues reached $621 billion in 2023, driven by accelerating GLP-1 prescriptions and an expanding post-pandemic market. How will the most consequential change in federal drug pricing policy affect the largest pharmacies and PBMs? to 1:30 p.m.
Pharmacies and Pharmacy Benefit Managers. The largest 15 pharmacies accounted for more than 75% of total dispensing revenues from retail, mail, long-term care, and specialty pharmacies. How will GoodRx and Mark Cuban Cost Plus Drug Company affect the pharmacy industry? to 1:30 p.m. d/b/a Drug Channels Institute.
Three is still the magic number for pharmacy benefit managers (PBMs). Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years. All rights reserved. This Feed is for personal non-commercial use only.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Prescription Market (press release) We’re offering special discounted pricing if you order before April 3, 2023. Prescription Market (press release) We’re offering special discounted pricing if you order before April 3, 2023.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022.
Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.
As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. Below, I review key findings on the economics and operations of these specialty pharmacies.
Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.
In Medicare Part D in 2024: The Seven Largest Companies' Preferred Pharmacy Networks and the Coming Collapse of the PDP Market , I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans. to 1:30 p.m.
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network. Links below. d/b/a Drug Channels Institute.
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.
Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks. DOWN THE DATA RABBIT HOLE.
In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr. Glaucomflecken helps UnitedHealthcare celebrate Doctors’ Day! Hope to see you there!
These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements. d/b/a Drug Channels Institute.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content